Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)

Jesper Jensen; Massar Omar; Caroline Kistorp; Christian Tuxen; Ida Gustafsson; Lars Køber; Finn Gustafsson; Jens Faber; Julie L. Forman; Jacob E. Møller; Morten Schou

doi:10.1161/CIRCULATIONAHA.120.053463

Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)

Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Julie L. Forman, Jacob E. Møller, Morten Schou^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Circulation
Vol/bind	143
Udgave nummer	22
Sider (fra-til)	2208-2210
Antal sider	3
ISSN	0009-7322
DOI	https://doi.org/10.1161/CIRCULATIONAHA.120.053463
Status	Udgivet - 2021

Adgang til dokumentet

10.1161/CIRCULATIONAHA.120.053463

Citationsformater

Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). / Jensen, Jesper; Omar, Massar; Kistorp, Caroline; Tuxen, Christian; Gustafsson, Ida; Køber, Lars ; Gustafsson, Finn ; Faber, Jens ; Forman, Julie L.; Møller, Jacob E.; Schou, Morten.

I: Circulation, Bind 143, Nr. 22, 2021, s. 2208-2210.

Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review

Jensen, Jesper ; Omar, Massar ; Kistorp, Caroline ; Tuxen, Christian ; Gustafsson, Ida ; Køber, Lars ; Gustafsson, Finn ; Faber, Jens ; Forman, Julie L. ; Møller, Jacob E. ; Schou, Morten. / Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). I: Circulation. 2021 ; Bind 143, Nr. 22. s. 2208-2210.

@article{c0b2710db58f4f65aa96a2f5394763a3,

title = "Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)",

keywords = "body composition, diabetes mellitus, type 2, empagliflozin, heart failure, insulin resistance, sodium-glucose transporter 2 inhibitors, REDUCED EJECTION FRACTION",

author = "Jesper Jensen and Massar Omar and Caroline Kistorp and Christian Tuxen and Ida Gustafsson and Lars K{\o}ber and Finn Gustafsson and Jens Faber and Forman, {Julie L.} and M{\o}ller, {Jacob E.} and Morten Schou",

year = "2021",

doi = "10.1161/CIRCULATIONAHA.120.053463",

language = "English",

volume = "143",

pages = "2208--2210",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "22",

}

TY - JOUR

T1 - Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)

AU - Jensen, Jesper

AU - Omar, Massar

AU - Kistorp, Caroline

AU - Tuxen, Christian

AU - Gustafsson, Ida

AU - Køber, Lars

AU - Gustafsson, Finn

AU - Faber, Jens

AU - Forman, Julie L.

AU - Møller, Jacob E.

AU - Schou, Morten

PY - 2021

Y1 - 2021

KW - body composition

KW - diabetes mellitus

KW - type 2

KW - empagliflozin

KW - heart failure

KW - insulin resistance

KW - sodium-glucose transporter 2 inhibitors

KW - REDUCED EJECTION FRACTION

U2 - 10.1161/CIRCULATIONAHA.120.053463

DO - 10.1161/CIRCULATIONAHA.120.053463

M3 - Letter

C2 - 34061581

VL - 143

SP - 2208

EP - 2210

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 22

ER -